MedTrace Logo

forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)

NCT01944618 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2016-09-13

No results posted yet for this study

Summary

The study purpose is to assess adverse events in patients with Type 2 diabetes who have newly been prescribed Forxiga for the management of glycemic control

Conditions

Interventions

DRUG

Forxiga

FORXIGA is a prescription medicine used with diet, exercise and sometimes other medicines (which may include metformin; insulin; a sulfonylurea medicine such as gliclazide, glimepiride and glibenclamide; or a dipeptidyl peptidase-4 inhibitor \[DPP 4 inhibitor\] such as sitagliptin or saxagliptin) to control the levels of blood sugar (glucose) in patients with type 2 diabetes mellitus.

Sponsors & Collaborators

Principal Investigators

  • Sophia Zoungas, Professor · Monash University

  • Christopher Reid, Professor · Monash University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01944618 on ClinicalTrials.gov